Adaptimmune TherapeuticsADAP
About: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Employees: 506
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
633% more call options, than puts
Call options by funds: $22K | Put options by funds: $3K
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0.58% less ownership
Funds ownership: 8.1% [Q4 2024] → 7.52% (-0.58%) [Q1 2025]
15% less funds holding
Funds holding: 79 [Q4 2024] → 67 (-12) [Q1 2025]
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
66% less capital invested
Capital invested by funds: $67M [Q4 2024] → $22.9M (-$44.2M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Mizuho Graig Suvannavejh | 402%upside $0.50 | Neutral Downgraded | 26 Jun 2025 |
Barclays Peter Lawson | 362%upside $0.46 | Underweight Maintained | 14 May 2025 |
Wells Fargo Yanan Zhu | 904%upside $1 | Equal-Weight Maintained | 14 May 2025 |
Financial journalist opinion









